Loading organizations...
Lexington Partners constructs and manages secondary private equity and co-investment funds, offering liquidity solutions and investment opportunities in the private markets. The firm pioneered the development of the institutional secondary market, establishing a significant presence across diversified secondaries, continuation vehicles, and co-investment strategies. Their approach emphasizes a time-tested market methodology and dedication to innovative solutions within alternative investments.
The firm was founded in 1994 by Brent R. Nicklas, who identified the nascent need for a structured secondary market for private equity interests. This foundational insight led to the creation of one of the earliest programs focused on acquiring private investment fund interests, subsequently expanding into discretionary co-investment programs to meet evolving market demands. The firm's early efforts in 1990 were instrumental in shaping the venture capital and buyout secondary markets.
Lexington Partners serves a broad base of institutional investors globally, providing access to diversified portfolios of private equity assets. The company's long-term vision centers on maintaining leadership in its core strategies, consistently delivering value through its established market approach, and upholding high standards to navigate the complexities of alternative asset management for its diverse client base.
Key people at Lexington Partners.
Lexington Partners was founded in 1994 by Brent R. Nicklas (Founder).
Key people at Lexington Partners.
Lexington Partners was founded in 1994 by Brent R. Nicklas (Founder).
Lexington Partners has 4 tracked investments across 3 companies. The latest tracked deal is $36.0M Series C in sovrn Holdings, Inc. in July 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2022 | sovrn Holdings, Inc. | $36.0M Series C | — | Bowery Capital, Foundry Group, High Alpha, Archer Venture Capital, Progress Ventures, Structural Capital |
| Oct 1, 2017 | KSQ Therapeutics | $76.0M Series B | Flagship Ventures, Polaris Partners | ARCH Venture Partners |
| Dec 8, 2014 | CardioKinetix | $50.0M Other Equity | Edwards Lifesciences | NEW Leaf Venture Partners, Panorama Capital, SV Health Investors, Tekla Capital Management, U.S. Venture Partners |
| Dec 1, 2014 | CardioKinetix | $50.0M Series F | Edwards Lifesciences | Johnson & Johnson Innovation, NEW Leaf Venture Partners, Saints Capital, SV Health Investors, Third Rock Ventures, VantagePoint Capital Partners, Panorama Capital, Tekla Capital Management, U.S. Venture Partners |